• Consensus Rating: Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 110.08%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$4.76
▼ -0.83 (-14.85%)

This chart shows the closing price for LPCN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Lipocine Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LPCN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LPCN

Analyst Price Target is $10.00
▲ +110.08% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Lipocine in the last 3 months. The average price target is $10.00, with a high forecast of $10.00 and a low forecast of $10.00. The average price target represents a 110.08% upside from the last price of $4.76.

This chart shows the closing price for LPCN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Lipocine.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/20/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/18/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/16/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/14/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/14/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/12/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/11/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/10/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/24/2024Alliance Global PartnersInitiated CoverageBuy$10.00
11/15/2022LADENBURG THALM/SH SHBoost Target$68.00
8/26/2021HC WainwrightBoost TargetPositive ➝ Buy$42.50 ➝ $59.50
6/24/2021Cantor FitzgeraldInitiated CoverageOverweight$51.00
5/27/2021HC WainwrightLower TargetBuy$51.00 ➝ $42.50
1/19/2021HC WainwrightReiterated RatingBuy$51.00
12/10/2020HC WainwrightReiterated RatingBuy
12/10/2020LADENBURG THALM/SH SHUpgradeNeutral ➝ Buy$51.00
5/27/2020HC WainwrightBoost TargetBuy$34.00 ➝ $51.00
11/11/2019HC WainwrightLower TargetBuy ➝ Hold$85.00 ➝ $34.00
11/11/2019LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral
(Data available from 11/10/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/14/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/14/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/13/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/13/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
8/12/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/11/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/11/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/10/2024

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Lipocine logo
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.
Read More

Today's Range

Now: $4.76
Low: $4.70
High: $5.93

50 Day Range

MA: $4.88
Low: $3.65
High: $6.09

52 Week Range

Now: $4.76
Low: $2.35
High: $11.79

Volume

66,659 shs

Average Volume

25,815 shs

Market Capitalization

$25.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18

Frequently Asked Questions

What sell-side analysts currently cover shares of Lipocine?

The following Wall Street research analysts have issued stock ratings on Lipocine in the last twelve months: Alliance Global Partners, and StockNews.com.
View the latest analyst ratings for LPCN.

What is the current price target for Lipocine?

0 Wall Street analysts have set twelve-month price targets for Lipocine in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 110.1%. Alliance Global Partners has the highest price target set, predicting LPCN will reach $10.00 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $10.00 for Lipocine in the next year.
View the latest price targets for LPCN.

What is the current consensus analyst rating for Lipocine?

Lipocine currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LPCN will outperform the market and that investors should add to their positions of Lipocine.
View the latest ratings for LPCN.

What other companies compete with Lipocine?

How do I contact Lipocine's investor relations team?

Lipocine's physical mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The specialty pharmaceutical company's listed phone number is (801) 994-7383 and its investor relations email address is [email protected]. The official website for Lipocine is www.lipocine.com. Learn More about contacing Lipocine investor relations.